



Invitation & Virtual Curriculum Overview 2023



You have been nominated by your centre's interventional oncology team to participate in a unique peer-to-peer multidisciplinary educational programme exploring the treatment of liver cancer.

A dynamic, interactive forum for hepatologists, gastroenterologists, medical oncologists and hepatopancreatobiliary (HPB) surgeons, SMARTT Y90 will explore the role of SIRT with TheraSphere Y90 as a versatile and safe therapy that can impact outcomes in liver cancer care.

Steering Committee

The programme has been developed in close co-operation with a panel of multidisciplinary specialists who will take an active role in the delivery of the curriculum.



Dr. Sherrie Bhoori Hepatologist, Milan, Italy



Prof. Deniz Balci Hepatopancreatobiliary & Transplant Surgeon, Istanbul, Turkey



Dr. Maria VarelaHepatologist,
Oviedo, Spain



Visit the website for latest details and to register for the **SMARTT Y90** virtual curriculum

ABOUT THERASPHERE™ Y90 THERAPY


The most powerful SIRT therapy available, the TheraSphere Y90 dose can be personalised to each patient to deliver highly targeted radiation to the tumour(s) while preserving healthy liver tissue.

Twenty years of clinical evidence supports the efficacy of TheraSphere Y90 throughout the HCC treatment pathway – including as a **valuable neoadjuvant therapy that can downstage and bridge patients to curative options.**¹

The EPOCH phase III RCT demonstrated a positive **progression-free survival benefit** when TheraSphere Y90 is used with systemic treatment in patients with metastatic liver tumours after failed first-line therapy,² while the importance of its role in the treatment of intrahepatic cholangiocarcinoma is increasingly widely recognised.³

HCC Case Example

Unlocking Access to Curative Surgery with Therasphere™: Effective Disease Control and Increased FLR




Baseline

12cm HCC in segments 5 and 8 with portal yein thrombosis



10 months post SIRT with TheraSphere

Atrophy of the treated right lobe with hypertrophy of the left lobe (FLR), allowing right hepatectomy to be performed



Post surgery

CT at day six post right hepatectomy

Reference

1. Lewandowski JR, Johnson GE, Kim E, et al. Use of Yttrium-90 (Y90) Glass Microspheres (TheraSphere[™]) as Neoadjuvant to Transplantation/Resection in Hepatocellular Carcinoma: Analyses from the LEGACY Study. J Clin Oncol 2021;39(3) suppl 300.

2. Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization with Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol 2021: Jco2101839.

3. Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020;6(1):51–59. doi:10.1001/jamaoncol.2019.3702.



THE SMARTT Y90 VIRTUAL CURRICULUM OVERVIEW 2023

Advances in Locoregional Neoadjuvant Therapy for HCC

Changing the Landscape in Patient Management

June 14
1 hour

Livestream <a>Workshop

Impact of TheraSphere Y90 therapy on liver function

Dr. Maria Varela, Hepatologist

TheraSphere Y90 therapy for downstaging: from right to left of BCLC

Dr. Sherrie Bhoori, Hepatologist

Role of downstaging in the expanding field of transplant oncology

Prof. Deniz Balci, Hepatopancreatobiliary & Transplant Surgeon



Livestream Workshop

Real-world case discussion from multidisciplinary team (MDT) perspective

Oct-Dec



Dedicated ask-theexpert interface for your centre Unique opportunity for a dedicated virtual meeting between your centre's multidisciplinary team and members of our Steering Committee and Faculty to raise specific questions and to explore how TheraSphere Y90 therapy might benefit your patients

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. 2023 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. PI-1595909-AA.



Visit the website for latest programme details and to register for the SMARTT Y90 virtual curriculum